BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IPX066: Phase III data

Top-line data from the double-blind, crossover, international Phase III ASCEND-PD trial in 84 evaluable patients with advanced PD showed that IPX066 met the primary endpoint of significantly reducing the percentage of "off" time in which patients experienced symptoms of their PD during waking hours from baseline as measured by patient diary vs. carbidopa-levodopa plus entacapone (33.5% vs. 10% reductions, p<0.0001). Specifically, IPX066 reduced "off" time from 5.9 hours at baseline to...

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >